219 related articles for article (PubMed ID: 37298919)
1. Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury.
Liang D; Wang W; Chen G; Li J; Dou G; Gan H; Han P; Du L; Gu R
Molecules; 2023 May; 28(11):. PubMed ID: 37298919
[TBL] [Abstract][Full Text] [Related]
2. [Preparation of liposomal artesunate dry powder inhalers and the effect on the acute lung injury of rats].
Hu YZ; Li M; Zhang TT; Jin YG
Yao Xue Xue Bao; 2016 Dec; 51(12):1906-12. PubMed ID: 29923696
[TBL] [Abstract][Full Text] [Related]
3. Paeonol loaded cyclodextrin metal-organic framework particles for treatment of acute lung injury via inhalation.
Li H; Zhu J; Wang C; Qin W; Hu X; Tong J; Yu L; Zhang G; Ren X; Li Z; Zhang J
Int J Pharm; 2020 Sep; 587():119649. PubMed ID: 32673767
[TBL] [Abstract][Full Text] [Related]
4. Naringenin-Loaded Dipalmitoylphosphatidylcholine Phytosome Dry Powders for Inhaled Treatment of Acute Lung Injury.
Yu Z; Liu X; Chen H; Zhu L
J Aerosol Med Pulm Drug Deliv; 2020 Aug; 33(4):194-204. PubMed ID: 32176552
[No Abstract] [Full Text] [Related]
5. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
6. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration.
Seow HC; Liao Q; Lau ATY; Leung SWS; Yuan S; Lam JKW
Int J Pharm; 2022 May; 619():121704. PubMed ID: 35358643
[TBL] [Abstract][Full Text] [Related]
8. Comparison of l-Carnitine and l-Carnitine HCL salt for targeted lung treatment of pulmonary hypertension (PH) as inhalation aerosols: Design, comprehensive characterization, in vitro 2D/3D cell cultures, and in vivo MCT-Rat model of PH.
Acosta MF; Muralidhran P; Abrahamson MD; Grijalva CL; Carver M; Tang H; Klinger C; Fineman JR; Black SM; Mansour HM
Pulm Pharmacol Ther; 2020 Dec; 65():101998. PubMed ID: 33556627
[TBL] [Abstract][Full Text] [Related]
9. A dry powder formulation for peripheral lung delivery and absorption of an anti-SARS-CoV-2 ACE2 decoy polypeptide.
Glieca S; Cavazzini D; Levati E; Garrapa V; Bolchi A; Franceschi V; Odau S; Ottonello S; Donofrio G; Füner J; Sonvico F; Bettini R; Montanini B; Buttini F
Eur J Pharm Sci; 2023 Dec; 191():106609. PubMed ID: 37838239
[TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
11. Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models.
Huang H; Hu G; Wang C; Xu H; Chen X; Qian A
Inflammation; 2014 Feb; 37(1):235-46. PubMed ID: 24045962
[TBL] [Abstract][Full Text] [Related]
12. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
13. Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters.
Jara MO; Warnken ZN; Sahakijpijarn S; Moon C; Maier EY; Christensen DJ; Koleng JJ; Peters JI; Hackman Maier SD; Williams Iii RO
Int J Pharm; 2021 Jun; 603():120701. PubMed ID: 33989748
[TBL] [Abstract][Full Text] [Related]
14. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
15. Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics.
Qi D; Jia B; Peng H; He J; Pi J; Guo P; Zhang Y; Deng X; Li J; Liu Z
Eur J Pharm Biopharm; 2023 Jul; 188():243-253. PubMed ID: 37224929
[TBL] [Abstract][Full Text] [Related]
16. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
17. [Development of an Inhalation Dry Powder Preparation Method without Heat-drying Process].
Ito T
Yakugaku Zasshi; 2023; 143(4):353-358. PubMed ID: 37005236
[TBL] [Abstract][Full Text] [Related]
18. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
[TBL] [Abstract][Full Text] [Related]
19. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
Albariqi AH; Ke WR; Khanal D; Kalfas S; Tang P; Britton WJ; Drago J; Chan HK
J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):239-251. PubMed ID: 35275749
[No Abstract] [Full Text] [Related]
20. Design and development of innovative microparticulate/nanoparticulate inhalable dry powders of a novel synthetic trifluorinated chalcone derivative and Nrf2 agonist.
Muralidharan P; Jones B; Allaway G; Biswal SS; Mansour HM
Sci Rep; 2020 Nov; 10(1):19771. PubMed ID: 33188247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
